Author:
Roubalová Eva,Kvardová Veronika,Hrstka Roman,Bořilová Šárka,Michalová Eva,Dubská Lenka,Müller Petr,Sova Petr,Vojtěšek Bořivoj
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference33 articles.
1. Adams M, A'Hern RP, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM (1998) Chemotherapy for ovarian cancer–a consensus statement on standard practice. Br J Cancer 78:1404–1406
2. Zlatanova J, Yaneva J, Leuba SH (1998) Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 12:791–799
3. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, Brabec V (1992) Biophysical analysis of DNA modified by 1, 2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 20:267–272. doi: 10.1093/nar/20.2.267
4. Eastman A (1999) The mechanism of action of cisplatin: from adducts to apoptosis. In: Lippert B (ed) Cisplatin, chemistry, and biochemistry of a leading anticancer drug, 1st edn. Helvetica Chimica Acta, Zürich, pp 111–135
5. Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D, Neca J, Sindlerova L, Kozubik A (2004) Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem 47:761–763. doi: 10.1021/jm030858+
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献